IRCT20200105046010N27Not yet recruiting未知
In- Vivo Bioequivalence study of Rivaroxaban tablet 10 and 20mg Jaber-ebne Hayyan Pharma with brand drug (XARELTO® 10 and 20mg Bayer, Germany) in Iranian healthy volunteers.
Jaber Ibn Hayyan Pharmaceutical Company0 sites24 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
Exclusion Criteria
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
Investigators
Similar Trials
Recruiting
Not Applicable
Bioequivalence study of Rivaroxaban 20 mg tabletBioequivalence study of Rivaroxaban 20 mg tablet (Tehran Darou) versus Xalerto® 20 mg (Bayer) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N4tehran darou Pharmaceutical Company24
Not yet recruiting
Not Applicable
A bioequivalence study of Rivaroxaban 20 mg tab compared to Xarelto 20 mg tab manufactured by Bayer in 24 healthy volunteers under fasting conditioIRCT20220209053979N1Pars Darou24
Not yet recruiting
Unknown
Bioequivalence study of Rivaroxaban 20mg tabletIRCT20200623047902N28Darou Darman Arang company24
Completed
Phase 1
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537405Bayer40
Recruiting
Phase 3
the effect of rivaroxaban on the prevention of deep vein thrombosis in nephrotic syndromephrotic syndrom.Nephrotic syndromeIRCT20220422054617N1Shiraz University of Medical Sciences20